Financhill
Buy
65

MLAB Quote, Financials, Valuation and Earnings

Last price:
$86.62
Seasonality move :
5.27%
Day range:
$90.14 - $92.65
52-week range:
$55.45 - $152.03
Dividend yield:
0.7%
P/E ratio:
141.31x
P/S ratio:
2.04x
P/B ratio:
2.70x
Volume:
59.2K
Avg. volume:
96.1K
1-year change:
-39.38%
Market cap:
$504M
Revenue:
$241M
EPS (TTM):
$0.65

Analysts' Opinion

  • Consensus Rating
    Mesa Laboratories, Inc. has received a consensus rating of Hold. The company's average rating is a Hold based on 1 Buy rating, 2 Hold ratings, and 0 Sell ratings.
  • Price Target Upside
    According to analysts' consensus price target of $104.50, Mesa Laboratories, Inc. has an estimated upside of 14.55% from its current price of $91.23.
  • Price Target Downside
    According to analysts, the lowest downside price target is $94.00 representing 100% downside risk from its current price of $91.23.

Fair Value

  • According to the consensus of 3 analysts, Mesa Laboratories, Inc. has 14.55% upside to fair value with a price target of $104.50 per share.

MLAB vs. S&P 500

  • Over the past 5 trading days, Mesa Laboratories, Inc. has underperformed the S&P 500 by -0.46% suggesting its relative strength compared to the major market average is weak at this time.

Share Buyback

  • Mesa Laboratories, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • Mesa Laboratories, Inc. has grown year-over-year revenues for 8 quarters straight. In the most recent quarter Mesa Laboratories, Inc. reported revenues of $65.1M.

Earnings Growth

  • Mesa Laboratories, Inc. has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Mesa Laboratories, Inc. reported earnings per share of $0.65.
Enterprise value:
645.1M
EV / Invested capital:
1.81x
Price / LTM sales:
2.04x
EV / EBIT:
37.43x
EV / Revenue:
2.61x
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
17.11x
Price / Operating cash flow:
13.37x
Enterprise value / EBITDA:
15.27x
Gross Profit (TTM):
$135.4M
Return On Assets:
0.86%
Net Income Margin (TTM):
1.51%
Return On Equity:
2.19%
Return On Invested Capital:
1.04%
Operating Margin:
12.25%
Trailing 12 Months Fiscal Quarters
Period Ending 2023-12-31 2024-12-31 2025-12-31 2024-12-31 2025-12-31
Income Statement
Revenue $212.9M $237.7M $247.5M $62.8M $65.1M
Gross Profit $107.3M $131.5M $135.4M $35.5M $37.6M
Operating Income $496K $19.1M $17.2M $5.8M $8M
EBITDA $34.8M $42.4M $42.3M $11.3M $13.7M
Diluted EPS $0.18 -$46.25 $0.65 -$0.31 $0.65
Period Ending 2021-12-31 2022-12-31 2023-12-31 2024-12-31 2025-12-31
Balance Sheet
Current Assets $121M $114.2M $118.4M $110.8M $105.6M
Total Assets $721.7M $663M $741.8M $437.1M $434.8M
Current Liabilities $46.8M $41.6M $44.2M $155.9M $54.4M
Total Liabilities $325.4M $275.8M $338.8M $281.9M $248.2M
Total Equity $396.3M $387.2M $403M $155.2M $186.7M
Total Debt $237M $189M $233M $208.1M $166.1M
Trailing 12 Months Fiscal Quarters
Period Ending 2023-12-31 2024-12-31 2025-12-31 2024-12-31 2025-12-31
Cash Flow Statement
Cash Flow Operations $43.8M $47.3M $41.5M $18.4M $18.8M
Cash From Investing -$82.8M -$3.1M -$3.8M -$813K -$732K
Cash From Financing $41.4M -$41.6M -$42.3M -$10.6M -$9.8M
Free Cash Flow $40.7M $43.3M $37.7M $17.6M $18M
MLAB
Sector
Market Cap
$504M
$23.4M
Price % of 52-Week High
60.01%
48.88%
Dividend Yield
0.7%
0%
Shareholder Yield
2.64%
-1.64%
1-Year Price Total Return
-39.38%
-21.81%
Beta (5-Year)
0.891
0.504
Dividend yield:
0.7%
Annualized payout:
$0.64
Payout ratio:
24.53%
Growth streak:
0 years

Technicals

8-day SMA
Buy
Level $89.75
200-day SMA
Buy
Level $83.20
Bollinger Bands (100)
Buy
Level 71.56 - 84.58
Chaikin Money Flow
Buy
Level 3.3M
20-day SMA
Buy
Level $85.97
Relative Strength Index (RSI14)
Buy
Level 61.38
ADX Line
Buy
Level 24.08
Williams %R
Neutral
Level -33.4302
50-day SMA
Buy
Level $82.62
MACD (12, 26)
Buy
Level 2.49
25-day Aroon Oscillator
Buy
Level 16
On Balance Volume
Neutral
Level 7.3M

Financial Scores

Sell
Altman Z-Score (Annual)
Level (1.3204)
Sell
CA Score (Annual)
Level (-0.7865)
Buy
Beneish M-Score (Annual)
Level (-2.9193)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (68.5025)
Buy
Piotroski F Score (Annual)
Level (6)
Buy
Quality Ratio Score
Level (8)
Buy
Fundamental Score
Level (6)

Revenue Forecast

Earnings per Share Forecast

Company Profile

Mesa Laboratories, Inc. engages in the design, manufacture, and market of instruments and disposable products utilized in healthcare, pharmaceutical, food and beverage, medical device, and petrochemical industries. It operates through the following segments: Sterilization and Disinfection Control, Clinical Genomics, Biopharmaceutical Development, and Calibration Solutions. The Sterilization and Disinfection Control segment manufactures and sells biological, cleaning, and chemical indicators. The Clinical Genomics segment division develops, manufactures and sells highly sensitive, low-cost, high-throughput genetic analysis tools and related consumables and services that enable clinical research labs and contract research organizations. The Biopharmaceutical Development segment caters and sells automated systems for protein analysis and peptide synthesis solutions. The Calibration Solutions segment focuses on the quality control products using principles of advanced metrology to enable customers to measure and calibrate critical parameters in applications such as renal care, environmental and process monitoring, gas flow, air quality and torque testing, primarily in medical device manufacturing, pharmaceutical manufacturing, laboratory and hospital environments. The company was founded by Luke R. Schmieder on March 26, 1982 and is headquartered in Lakewood, CO.

Stock Forecast FAQ

In the current month, MLAB has received 1 Buy ratings 2 Hold ratings, and 0 Sell ratings. The MLAB average analyst price target in the past 3 months is $104.50.

  • Where Will Mesa Laboratories, Inc. Stock Be In 1 Year?

    According to analysts, the consensus estimate is that Mesa Laboratories, Inc. share price will rise to $104.50 per share over the next 12 months.

  • What Do Analysts Say About Mesa Laboratories, Inc.?

    Analysts are divided on their view about Mesa Laboratories, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Mesa Laboratories, Inc. is a Sell and believe this share price will drop from its current level to $94.00.

  • What Is Mesa Laboratories, Inc.'s Price Target?

    The price target for Mesa Laboratories, Inc. over the next 1-year time period is forecast to be $104.50 according to 3 Wall Street analysts, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.

  • Is MLAB A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for Mesa Laboratories, Inc. is a Hold. 2 of 3 analysts rate the stock a Hold at this time.

  • How Can I Buy Shares Of MLAB?

    You can purchase shares of Mesa Laboratories, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Mesa Laboratories, Inc. shares.

  • What Is The Mesa Laboratories, Inc. Share Price Today?

    Mesa Laboratories, Inc. was last trading at $86.62 per share. This represents the most recent stock quote for Mesa Laboratories, Inc.. Yesterday, Mesa Laboratories, Inc. closed at $91.23 per share.

  • How To Buy Mesa Laboratories, Inc. Stock Online?

    In order to purchase Mesa Laboratories, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

Related Companies

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Will UnitedHealth Stock Recover?
Will UnitedHealth Stock Recover?

Shares of embattled health insurance giant UnitedHealth (NYSE:UNH) plummeted by…

Is Lumentum The Best Laser Stock to Buy?
Is Lumentum The Best Laser Stock to Buy?

Though certainly less well-known than the huge tech businesses that…

Is Planet Fitness Stock Undervalued?
Is Planet Fitness Stock Undervalued?

Planet Fitness (NYSE:PLNT) has had a difficult 12 months, retreating…

Stock Ideas

Buy
56
Is NVDA Stock a Buy?

Market Cap: $4.6T
P/E Ratio: 65x

Buy
58
Is AAPL Stock a Buy?

Market Cap: $4T
P/E Ratio: 37x

Sell
40
Is GOOG Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 29x

Alerts

Buy
91
TDC alert for Feb 12

Teradata Corp. [TDC] is down 12.33% over the past day.

Buy
67
DIOD alert for Feb 12

Diodes, Inc. [DIOD] is down 7.41% over the past day.

Buy
77
VRT alert for Feb 12

Vertiv Holdings Co. [VRT] is down 4.41% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock